Web19 de fev. de 2024 · Although prior study has shown that high-intensity statins are safe in Asian, 24,25 statin adverse reactions occur dose-dependently. 26–28 In addition, the deleterious effect of very low plasma LDL-C level is still in doubt and some experts question whether it may result in an increased risk of intracerebral hemorrhage. 29,30 Therefore, … WebFor all statins Common or very common Arthralgia; asthenia; constipation; diarrhoea; dizziness; flatulence; gastrointestinal discomfort; headache; muscle complaints; …
Improving Statin Tolerance in Elderly Patients
WebPerson at high CVD risk reports potential intolerance to recommended high intensity statin treatment New onset or worsening of muscle symptoms since starting ... Offer low or moderate dose of a higher intensity statin (Atorvastatin 10 or 20 mg OD, or Rosuvastatin 5 or 10mg OD) Measure Creatine Kinase (CK) Assess severity of symptoms +/- repeat ... Web12 de abr. de 2024 · Ezetimibe plus moderate-intensity statin versus high-intensity statin. 22 February 2024. Browse by topic. Cardiology. Dermatology. Drug reviews and drug licensing. Gastrointestinal. ... BNF update: Recent updates from the BNF (BNF 85) 7 March 2024. CONTENT. Latest content; Browse by collection; Most read articles; inguinal hernia repair mesh failure
NAPLEX Question of the Week: Statin Equivalencies
Web17 de mar. de 2024 · Statin Treatment Recommendations. The following are guideline recommendations for statin treatment: Patients ages 20-75 years and LDL-C ≥190 mg/dl, use high-intensity statin without risk assessment. T2DM and age 40-75 years, use moderate-intensity statin and risk estimate to consider high-intensity statins. WebPrescribing lipid-modification therapy (high-intensity statin or ezetimibe) to achieve a target reduction in LDL cholesterol concentration of greater than 50% from baseline. Considering the need for antihypertensive treatment in people with hypertension, and the need for aspirin for the primary prevention of CVD. Web2 de mai. de 2024 · Lamprecht D.G., Shaw P.B., King J.B., Hogan K.N., Olson K.L. "Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service". J Clin Lipidol 2024;12:999-1007. Crossref Medline Google Scholar; 10. mizuno women\u0027s softball pants size chart